Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.

Cancer research - 1 Jul 2007

Shi Jun, Zhao Yan, Ishii Takefumi, Hu Wenyang, Sozer Selcuk, Zhang Wei, Bruno Edward, Lindgren Valerie, Xu Mingjiang, Hoffman Ronald

Abstract excerpt

Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltran...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Azacitidine
Share to Decitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA (Cytosine-5-)-Methyltransferases

Share to Hydroxamic Acids

Share to Primary Myelofibrosis

Share to Protein Synthesis Inhibitors

Share to Receptors, CXCR4

Source

Identifiers

PMID: 17616702
DOI: 10.1158/0008-5472.CAN-07-0572

Genes

CXCR4
JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17616702-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.PMID 17616702Read ↗

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.Semantic proximity Read ↗

Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.Semantic proximity Read ↗

Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potentialSemantic proximity Read ↗

Differential Effects of Epigenetic Modifiers on the Expansion and Maintenance of Human Cord Blood Stem/Progenitor CellsSemantic proximity Read ↗

Improvement of Cardiac Function in Mouse Myocardial Infarction after Transplantation of Epigenetically-Modified Bone Marrow Progenitor CellsSemantic proximity Read ↗

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).Semantic proximity Read ↗

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.Semantic proximity Read ↗

Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.